(Reuters) – GSK on Wednesday lifted its full-year forecast, boosted by reinvigorated demand for its blockbuster Shingrix vaccine, days after overhauling the business with the spinoff of its consumer health unit.
GSK now expects 2022 sales to rise 6% to 8% and adjusted operating profit to increase by 13% to 15%, excluding any contributions from the company’s COVID-19 solutions business.
Previously, the company had forecast full-year sales to grow 5% to 7% and adjusted operating profit to rise 12% to 14%.
(Reporting by Natalie Grover in London, Editing by Louise Heavens)
